Category Archives: Stem Cell Videos

REDWOOD CITY, Calif.--(BUSINESS WIRE)--

OncoMed Pharmaceuticals, Inc., a clinical stage, research and discovery company developing novel therapeutics that target cancer stem cells, today announced clinical progress with two of its Notch pathway product candidates, resulting in $8 million in milestone payments from the companys strategic collaborator GlaxoSmithKline (GSK).

Anti-Notch2/3 (OMP-59R5)

OncoMed has initiated a Phase 1b/2 clinical trial in its anti-Notch2/3 antibody (OMP-59R5) program. In the Phase 1b/2 ALPINE trial (Antibody therapy in first-Line Pancreatic cancer Investigating anti-Notch Efficacy and safety), Anti-Notch2/3 is being tested in combination with gemcitabine in first-line advanced pancreatic cancer patients. Following a Phase 1b safety run-in, a randomized Phase 2 clinical trial will proceed in these patients to compare the efficacy of standard-of-care gemcitabine either with Anti-Notch2/3 or with placebo. The two primary endpoints of the Phase 2 part of the trial will be progression-free survival (PFS) in the Anti-Notch2/3 arm compared to a placebo arm in all patients, as well as in patients who have a particular biomarker. Key secondary and exploratory endpoints include overall survival, response rate, and safety, and these endpoints will be assessed in all patients, as well as in the biomarker positive subset of patients.

Dr. Lon Smith, from the South Texas Accelerated Research Therapeutics (START) Center for Cancer Care, who treated the first patient dosed in the ALPINE study, noted, This is an exciting new clinical trial with a novel anti-cancer treatment that we hope will have a big impact for patients with pancreatic cancer. The fact that the trial also includes a predictive biomarker to potentially identify patients who might gain greater clinical benefit from Anti-Notch2/3 is also a new and exciting direction in the experimental treatment of patients with pancreatic cancer.

Anti-Notch1 (OMP-52M51)

An Investigational New Drug (IND) application filed by OncoMed has been accepted by the FDA, thereby allowing OncoMed to advance its anti-Notch1 antibody (OMP-52M51) to clinical testing. OncoMed plans to initiate a single-agent, dose escalation and expansion Phase 1 clinical trial in hematologic cancers in 2012 and plans to file an additional IND application later in 2012 in solid tumors. The clinical trials will assess safety, pharmacokinetics, pharmacodynamics, and initial evidence of efficacy via a biomarker-based patient selection approach.

The OMP-59R5 Phase 1b/2 clinical program is our first Phase 2 trial and represents a significant advancement in the companys pipeline of anti-cancer stem cell therapies, said Paul Hastings, President and Chief Executive Officer of OncoMed Pharmaceuticals. In addition, the acceptance from the FDA to begin clinical testing for OMP-52M51 represents the fifth product candidate from our R&D platform to be cleared to enter clinical testing. For both programs, we have developed comprehensive biomarker strategies to facilitate efficient development in patients we believe will be most likely to benefit from targeted Notch pathway signaling blockade, added Hastings.

OMP-59R5 and OMP-52M51 are part of OncoMeds collaboration with GlaxoSmithKline. In December 2007, OncoMed and GSK entered into a broad strategic alliance to discover and develop novel product candidates targeting cancer stem cells via Notch pathway signaling modulation. GSK retains an option through the end of certain Phase 2 clinical trials to obtain an exclusive license to OMP-59R5. GSK also retains an option through the end of certain Phase 1 or certain Phase 2 clinical trials to obtain an exclusive license to OMP-52M51.

About Cancer Stem Cells

View post:
OncoMed Pharmaceuticals Advances Two Notch Pathway Product Candidates in Clinical Development

NEWARK, Calif., Oct. 4, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM) today announced that the first patient in its Phase I/II clinical trial in dry age-related macular degeneration (AMD) has been enrolled and transplanted. The trial is designed to evaluate the safety and preliminary efficacy of the Company's proprietary HuCNS-SC(R) product candidate (purified human neural stem cells) as a treatment for dry AMD, and the patient was transplanted with the cells yesterday at the Retina Foundation of the Southwest (RFSW) in Dallas, Texas, one of the leading independent vision research centers in the United States. AMD afflicts approximately 30 million people worldwide and is the leading cause of vision loss and blindness in people over 55 years of age.

"This trial signifies an exciting extension of our on-going clinical research with neural stem cells from disorders of the brain and spinal cord to now include the eye," said Stephen Huhn, MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc. "Studies in the relevant animal model demonstrate that the Company's neural stem cells preserve vision in animals that would otherwise go blind and support the therapeutic potential of the cells to halt retinal degeneration. Unlike others in the field, we are looking to intervene early in the course of the disease with the goal of preserving visual function before it is lost."

David G. Birch, Ph.D., Chief Scientific and Executive Officer of the RFSW and Director of the Rose-Silverthorne Retinal Degenerations Laboratory and principal investigator of the study, added, "We are excited to be working with StemCells on this ground breaking clinical trial. There currently are no effective treatments for dry AMD, which is the most common form of the disease, and there is a clear need to explore novel therapeutic approaches."

In February 2012, the Company published preclinical data that demonstrated HuCNS-SC cells protect host photoreceptors and preserve vision in the Royal College of Surgeons (RCS) rat, a well-established animal model of retinal disease which has been used extensively to evaluate potential cell therapies. Moreover, the number of cone photoreceptors, which are responsible for central vision, remained constant over an extended period, consistent with the sustained visual acuity and light sensitivity observed in the study. In humans, degeneration of the cone photoreceptors accounts for the unique pattern of vision loss in dry AMD. The data was published in the international peer-reviewed European Journal of Neuroscience.

About Age-Related Macular Degeneration

Age-related macular degeneration refers to a loss of photoreceptors (rods and cones) from the macula, the central part of the retina. AMD is a degenerative retinal disease that typically strikes adults in their 50s or early 60s, and progresses painlessly, gradually destroying central vision. According to the RFSW website, there are approximately 1.75 million Americans age 40 years and older with some form of age-related macular degeneration, and the disease continues to be the number one cause of irreversible vision loss among senior citizens in the United States with more than seven million at risk of developing AMD.

About the Trial

The Phase I/II trial will evaluate the safety and preliminary efficacy of HuCNS-SC cells as a treatment for dry AMD. The trial will be an open-label, dose-escalation study, and is expected to enroll a total of 16 patients. The HuCNS-SC cells will be administered by a single injection into the space beneath the retina in the most affected eye. Patients' vision will be evaluated using both conventional and advanced state-of-the-art methods of ophthalmological assessment. Evaluations will be performed at predetermined intervals over a one-year period to assess safety and signs of visual benefit. Patients will then be followed for an additional four years in a separate observational study. Patients interested in participating in the clinical trial should contact the site at (214) 363-3911.

About HuCNS-SC Cells

StemCells' proprietary product candidate, HuCNS-SC cells, is a highly purified composition of human neural stem cells that are expanded and stored as banks of cells. The Company's preclinical research has shown that HuCNS-SC cells can be directly transplanted in the central nervous system (CNS) with no sign of tumor formation or adverse effects. Because the transplanted HuCNS-SC cells have been shown to engraft and survive long-term, there is the possibility of a durable clinical effect following a single transplantation. StemCells believes that HuCNS-SC cells may have broad therapeutic application for many diseases and disorders of the CNS, and to date has demonstrated human safety data from completed and ongoing clinical studies.

Excerpt from:
StemCells, Inc. Announces First Transplant of Neural Stem Cells Into Patient in Clinical Trial for Dry Age-Related ...

IRVINE High school sophomore Derek Le said he's always been interested in science. But it wasn't until he saw how researchers could use stem cells to repair tissue damaged by heart attacks that Le thought science could be his future career.

"Wow, this is so amazing," said Le, a student from Westminster High. "They can create cells to fix people's hearts. I think I want to do something like this."

Emily Nordhoff, Junior Research Specialist is harnessed in a body weight support system that is used to measure walking patterns. More than 250 high school students took a tour of UC Irvine's Stem Cell program to learn about stem cell research.

CHRISTINE COTTER, FOR THE REGISTER

ADVERTISEMENT

The center was established at UC Irvine in 2010 with help of a $10 million endowment from PIMCO founder and his wife.

Mission

The center's goals include training new researchers, providing state-of-the-art tissue culture labs and equipment, and testing new technologies and products related to stem cells research.

Accomplishments

Recent accomplishments include: securing first federally approved embryonic stem cell based therapy to go to clinical trial; developing of bone marrow stem cell treatment for stroke patients; and development of treatments for retinitis pigmentosa and macular degeneration.

See the article here:
UCI stem cell center awes students

Newswise LOS ANGELES (Oct. 2, 2012) Researchers at Cedars-Sinais Maxine Dunitz Neurosurgical Institute have found that a blood vessel-building gene boosts the ability of human bone marrow stem cells to sustain pancreatic recovery in a laboratory mouse model of insulin-dependent diabetes.

The findings, published in a PLoS ONE article of the Public Library of Science, offer new insights on mechanisms involved in regeneration of insulin-producing cells and provide new evidence that a diabetics own bone marrow one day may be a source of treatment.

Scientists began studying bone marrow-derived stem cells for pancreatic regeneration a decade ago. Recent studies involving several pancreas-related genes and delivery methods transplantation into the organ or injection into the blood have shown that bone marrow stem cell therapy could reverse or improve diabetes in some laboratory mice. But little has been known about how stem cells affect beta cells pancreas cells that produce insulin or how scientists could promote sustained beta cell renewal and insulin production.

When the Cedars-Sinai researchers modified bone marrow stem cells to express a certain gene (vascular endothelial growth factor, or VEGF), pancreatic recovery was sustained as mouse pancreases were able to generate new beta cells. The VEGF-modified stem cells promoted growth of needed blood vessels and supported activation of genes involved in insulin production. Bone marrow stem cells modified with a different gene, PDX1, which is important in the development and maintenance of beta cells, resulted in temporary but not sustained beta cell recovery.

Our study is the first to show that VEGF contributes to revascularization and recovery after pancreatic injury. It demonstrates the possible clinical benefits of using bone marrow-derived stem cells, modified to express that gene, for the treatment of insulin-dependent diabetes, said John S. Yu, MD, professor and vice chair of the Department of Neurosurgery at Cedars-Sinai, senior author of the journal article.

Diabetes was reversed in five of nine mice treated with the injection of VEGF-modified cells, and near-normal blood sugar levels were maintained through the remainder of the six-week study period. The other four mice survived and gained weight, suggesting treatment was beneficial even when it did not prompt complete reversal. Lab studies later confirmed that genetically-modified cells survived and grew in the pancreas and supported the repopulation of blood vessels and beta cells.

Anna Milanesi, MD, PhD, working in Yus lab as an endocrinology fellow, is the articles first author. The researchers cautioned that although this and other related studies help scientists gain a better understanding of the processes and pathways involved in pancreatic regeneration, more research is needed before human clinical trials can begin.

Insulin-dependent diabetes occurs when beta cells of the pancreas fail to produce insulin, a hormone that regulates sugar in the blood. Patients must take insulin injections or consider transplantation of a whole pancreas or parts of the pancreas that make insulin, but transplantation carries the risk of cell rejection.

# # #

PLoS ONE: Beta-cell Regeneration Mediated by Human Bone Marrow Mesenchymal Stem Cells.

See more here:
Study Sheds Light on Bone Marrow Stem Cell Therapy for Pancreatic Recovery

More than 200 high school students, including those in the Costa Mesa-based Coastline Regional Occupational Program, got an inside look at the stem cell research at UC Irvine.

UCI's Sue and Bill Gross Stem Cell Research Center opened its doors Monday for the first of several events to celebrate International Stem Cell Awareness Day, which is Wednesday. The university is also hosting a science symposium from 9 a.m. to 5 p.m. Wednesday with a Meet the Scientists interactive forum from 5 to 5:45 p.m.

"I think it is just an exciting time for this field, and what we want to do is get the word out," said Director Peter Donovan.

In a little more than decade, stem cells have moved from research to being used in humans, such a quick pace that people often compare it to the race to get a man on the moon, but stem cell research is moving much faster, Donovan said.

The speed partly comes from a feeling that the field can offer new treatment for diseases that have none, he said.

At UCI, about 200 scientists from graduate students to technicians to professors are studying stem cells and researching treatments for spinal cord and traumatic brain injuries, and diseases such as Alzheimer's and Huntington's.

"We truly believe that the work that we do here will transform the world," Donovan said.

UCI scientist Aileen Anderson gave students an overview of stem cells and explained her research, which led to the first human clinical trials of using neural stem cells to repair spinal cord injuries.

Anderson said understanding spinal cord injuries can have a broader impact on the research for a treatment in others areas, such as strokes, ALS and traumatic brain injuries.

"Stem cell research might be able to help a lot of different diseases," she said.

Read the original post:
Seeing the study of stem cells

Public release date: 2-Oct-2012 [ | E-mail | Share ]

Contact: Sandy Van sandy@prpacific.com 808-526-1708 Cedars-Sinai Medical Center

LOS ANGELES (Oct. 2, 2012) Researchers at Cedars-Sinai's Maxine Dunitz Neurosurgical Institute have found that a blood vessel-building gene boosts the ability of human bone marrow stem cells to sustain pancreatic recovery in a laboratory mouse model of insulin-dependent diabetes.

The findings, published in a PLOS ONE article of the Public Library of Science, offer new insights on mechanisms involved in regeneration of insulin-producing cells and provide new evidence that a diabetic's own bone marrow one day may be a source of treatment.

Scientists began studying bone marrow-derived stem cells for pancreatic regeneration a decade ago. Recent studies involving several pancreas-related genes and delivery methods transplantation into the organ or injection into the blood have shown that bone marrow stem cell therapy could reverse or improve diabetes in some laboratory mice. But little has been known about how stem cells affect beta cells pancreas cells that produce insulin or how scientists could promote sustained beta cell renewal and insulin production.

When the Cedars-Sinai researchers modified bone marrow stem cells to express a certain gene (vascular endothelial growth factor, or VEGF), pancreatic recovery was sustained as mouse pancreases were able to generate new beta cells. The VEGF-modified stem cells promoted growth of needed blood vessels and supported activation of genes involved in insulin production. Bone marrow stem cells modified with a different gene, PDX1, which is important in the development and maintenance of beta cells, resulted in temporary but not sustained beta cell recovery.

"Our study is the first to show that VEGF contributes to revascularization and recovery after pancreatic injury. It demonstrates the possible clinical benefits of using bone marrow-derived stem cells, modified to express that gene, for the treatment of insulin-dependent diabetes," said John S. Yu, MD, professor and vice chair of the Department of Neurosurgery at Cedars-Sinai, senior author of the journal article.

Diabetes was reversed in five of nine mice treated with the injection of VEGF-modified cells, and near-normal blood sugar levels were maintained through the remainder of the six-week study period. The other four mice survived and gained weight, suggesting treatment was beneficial even when it did not prompt complete reversal. Lab studies later confirmed that genetically-modified cells survived and grew in the pancreas and supported the repopulation of blood vessels and beta cells.

Anna Milanesi, MD, PhD, working in Yu's lab as an endocrinology fellow, is the article's first author. The researchers cautioned that although this and other related studies help scientists gain a better understanding of the processes and pathways involved in pancreatic regeneration, more research is needed before human clinical trials can begin.

Insulin-dependent diabetes occurs when beta cells of the pancreas fail to produce insulin, a hormone that regulates sugar in the blood. Patients must take insulin injections or consider transplantation of a whole pancreas or parts of the pancreas that make insulin, but transplantation carries the risk of cell rejection.

See the original post:
Cedars-Sinai study sheds light on bone marrow stem cell therapy for pancreatic recovery

ScienceDaily (Oct. 2, 2012) The team led by Manel Esteller, director of the Cancer Epigenetics and Biology Program in the Bellvitge Biomedical Research Institute (IDIBELL), Professor of Genetics at the University of Barcelona and ICREA researcher, has identified epigenetic changes that occur in adult stem cells to generate different body tissues.

The finding is published this week in The American Journal of Pathology.

The genome of every single cell in the human body is the same, regardless of their appearance and function. Therefore the activity of the tissues and organs and its disorders in complex diseases, such as cancer, cannot be fully explained by the genome. It is necessary something more, and part of the explanation is provided by epigenetics, which is defined as "the inheritance of DNA activity that does not depend on strict sequence of it." That is, if genetics is the alphabet, spelling would be the epigenetics, which refers to chemical changes in our genetic material and their regulatory proteins. The most known epigenetic mark is the addition of a methyl group to DNA. Thus, the epigenome is getting all the epigenetic marks of a living being.

Adult stem cells have an enormous potential to regenerate damaged organs and their use also avoids ethical complications involving embryonic stem cells, as well as technical problems arising from induced stem cells. In this study, researchers have isolated stem cells from body fat and transformed them into muscle and bone cells. Then, it was necessary to know how much resembled are the cells created in the laboratory with those present in one individual and if they were biologically secured enough to be implanted in patients. The study shows that the epigenome of the cells obtained in culture closely resembles that of skeletal muscle cells and they are spontaneously present in nature, although not completely identical.

A key point of the study is that muscle and bone cells produced in the laboratory do not have the tumour epigenome derived from these tumour tissues (rhabdomyosarcoma and osteosarcoma, respectively) so they are safe from a biological perspective. The study coordinator, Manel Esteller, stresses that the research "demonstrates the usefulness of epigenetics in determining the degree of maturity and biosecurity of differentiated tissues used in regenerative medicine against different diseases."

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by IDIBELL-Bellvitge Biomedical Research Institute.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

See the rest here:
Adult stem cells change their epigenome to generate new organs

ScienceDaily (Oct. 2, 2012) Researchers at Cedars-Sinai's Maxine Dunitz Neurosurgical Institute have found that a blood vessel-building gene boosts the ability of human bone marrow stem cells to sustain pancreatic recovery in a laboratory mouse model of insulin-dependent diabetes.

The findings, published in a PLoS ONE article of the Public Library of Science, offer new insights on mechanisms involved in regeneration of insulin-producing cells and provide new evidence that a diabetic's own bone marrow one day may be a source of treatment.

Scientists began studying bone marrow-derived stem cells for pancreatic regeneration a decade ago. Recent studies involving several pancreas-related genes and delivery methods -- transplantation into the organ or injection into the blood -- have shown that bone marrow stem cell therapy could reverse or improve diabetes in some laboratory mice. But little has been known about how stem cells affect beta cells -- pancreas cells that produce insulin -- or how scientists could promote sustained beta cell renewal and insulin production.

When the Cedars-Sinai researchers modified bone marrow stem cells to express a certain gene (vascular endothelial growth factor, or VEGF), pancreatic recovery was sustained as mouse pancreases were able to generate new beta cells. The VEGF-modified stem cells promoted growth of needed blood vessels and supported activation of genes involved in insulin production. Bone marrow stem cells modified with a different gene, PDX1, which is important in the development and maintenance of beta cells, resulted in temporary but not sustained beta cell recovery.

"Our study is the first to show that VEGF contributes to revascularization and recovery after pancreatic injury. It demonstrates the possible clinical benefits of using bone marrow-derived stem cells, modified to express that gene, for the treatment of insulin-dependent diabetes," said John S. Yu, MD, professor and vice chair of the Department of Neurosurgery at Cedars-Sinai, senior author of the journal article.

Diabetes was reversed in five of nine mice treated with the injection of VEGF-modified cells, and near-normal blood sugar levels were maintained through the remainder of the six-week study period. The other four mice survived and gained weight, suggesting treatment was beneficial even when it did not prompt complete reversal. Lab studies later confirmed that genetically-modified cells survived and grew in the pancreas and supported the repopulation of blood vessels and beta cells.

Anna Milanesi, MD, PhD, working in Yu's lab as an endocrinology fellow, is the article's first author. The researchers cautioned that although this and other related studies help scientists gain a better understanding of the processes and pathways involved in pancreatic regeneration, more research is needed before human clinical trials can begin.

Insulin-dependent diabetes occurs when beta cells of the pancreas fail to produce insulin, a hormone that regulates sugar in the blood. Patients must take insulin injections or consider transplantation of a whole pancreas or parts of the pancreas that make insulin, but transplantation carries the risk of cell rejection.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

The rest is here:
New study sheds light on bone marrow stem cell therapy for pancreatic recovery

For more than 40 years, Lesley Kelly of Glasgow, Scotland, lived with third-degree burns that stretched over 60 percent of her body.

Kelly was 2 years old when she fell into a bathtub filled with hot water that scorched most of the right side of her body. She lost full range of motion around many of her joints.

"When you have bad scarring, the buildup is very thick and has no elasticity," said Kelly, 45, whose right elbow was most affected by the buildup of scar tissue. "The problem with thermal burn scarring [is that] it's hard to get the range of motion."

Kelly underwent numerous reparative surgeries through the years, but the scar tissue continued to grow back. The procedures did not lessen the look of her scars.

In 2011, Kelly underwent a new, experimental procedure that used stem cells from her own fat tissue to repair the buildup around her right elbow.

Surgeons cleaned the scar buildup around the elbow and used liposuction to pull fat from off Kelly's waist. They separated the fat cells from the stem and regenerative cells, which were then injected into the wound on Kelly's arm. The procedure took less than two hours.

Within months, Kelly was able to regain 40 degrees of motion that she had lost more than 40 years ago.

Cytori Therapeutics, Inc.

"If this technology was available earlier in my life, my scars would not have been as bad," said Kelly.

There are an estimated 50,000 to 70,000 burn cases each year in the U.S., according to the American Burn Association.

Go here to read the rest:
New Therapy May Help Burn Victims

Miami, FL (PRWEB) October 01, 2012

The Conference was geared to offer attendees the opportunity to attain updated information regarding current and future applications in cord blood stem cells as well as the ongoing research in regenerative medicine. It took place at the Charles Hotel in Cambridge Massachusetts, in the vicinity of Harvard University, minutes from the heart of Boston.

The event was attended by 300+ notable and prominent doctors, scientists and regulators in the field of stem and featured numerous keynote speakers. The program kicked-off with the chairmans opening remarks on the perspective on the cord blood market. Entities involved in the collection, processing, cryopreservation, transplantation and research shared their and experiences with the rapidly evolving future of cord blood stem cells and related tissues. Some presentation topics included were:

Umbilical cord blood preservation is a process by which blood is collected from the umbilical cord of a newborn baby and is stored cryogenically in a specially-designated bank. According to the National Marrow Donor Program, cord blood contains cells that can be transfused to a patient to treat various diseases, including lymphoma and leukemia. Currently, there are approximately 80 treatable diseases and the list of illnesses continue to grow. Cord blood is rich in stem cells and there is less risk for the recipients immune system to reject the cells, because certain immune cells found in the cord blood are not mature. Cord blood can be used to treat the child from whom the blood was collected as well as some first-degree relatives who are a close genetic match, such as family members. Additionally, patients can get the treatment in about three weeks - as opposed to six to eight for bone marrow from an adult donor.

A persons blood stem cell type is inherited, which means a patient is more likely to find a matched donor from within their own ethnic group, said GeneCells Director of Operations, Jose Cirino. More than half of cord blood donations and privately banked cord blood in the United States are from Caucasians while minorities remain underrepresented. By increasing the awareness of cord blood advantages among minorities, there is a potential for increased access to therapies for more people.

The shortage, or lack of availability, affects patients of African, Asian, Hispanic and Native American Indian descent. Since patients who need a transplant are more likely to find a match within their own race, Cirino adds it is important that the pool of donors reflects the overall community.

Why isn't everyone banking these cells? What transpires is that people are not informed about stem cell banking and some have never even heard of it. Most people are not aware they have stem cells in their body, they believe that stem cells only come from human embryos since that is what is mainly discussed in politics and the news. However, this is not the case. These cells are found in adults and there are no moral, ethical or political issues surrounding these cells.

The amazing thing about these cells, aside from their potential to treat a variety of different diseases, is that for the most part they can be harvested from the individual through relatively minimally invasive procedures and can be cryogenically frozen (at a temperature of -321 F) and stored for decades until a disease manifests or they are needed for cell-based therapies added GeneCells Director of Research & Laboratory Operations, Dr. Todd R. Flower.

GeneCell International specializes in the collection, transport, processing and cryogenic storage of adult stem cells from various sources including; umbilical cord blood, cord tissue, dental pulp and adipose tissue (fat) that can later be used to treat a variety of diseases. The laboratory is also involved in scientific research and development with a range of stem cells from various adult tissues. The facility is governed and inspected by the FDA as well several other regulating bodies to ensure the safety of these cellular therapies.

Alongside its commitment to educating the public on the benefits of cord blood preservation, GeneCell is committed to being on the forefront of stem cell research. GeneCell International is the only Cord Blood, Cord Tissue and Dental Pulp Processing and Cryogenic Storage Laboratory to offer this cutting-edge, regenerative medicine technology in Miami, Florida.

Continued here:
GeneCell International, Miami’s Only and Preferred Cord Blood Laboratory, Participates in The Stem Cells USA & World ...